• ABPI Website
  • Media
  • ABPI response to proposed UK-‘Rest of the World’ FTA negotiation approaches

ABPI response to proposed UK-‘Rest of the World’ FTA negotiation approaches

The UK Government has published its proposed approach to negotiations for Free Trade Agreements (FTAs) with other ‘priority partners’, besides the EU.

As the UK looks to strike new trade agreements across the world, we share the Government’s ambition to make the UK a leading global hub for life sciences. Securing the UK’s reputation as an attractive destination for global research and development investment will be key to achieving this. Richard Torbett

In a Written Ministerial Statement, the Secretary of State for International Trade Liz Truss set out the Government’s key priority to deepen trade and investment relationships with the USA, Japan, Australia and New Zealand.

Richard Torbett, Chief Executive of the ABPI, said:

“As the UK looks to strike new trade agreements across the world, we share the Government’s ambition to make the UK a leading global hub for life sciences. 

“Securing the UK’s reputation as an attractive destination for global research and development investment will be key to achieving this.

“Our priority is for the UK and EU to explore the best way to cooperate on medicine regulation, as both sides have already agreed to do in the next stage of negotiations.”

Regarding a UK-US Free Trade Agreement, the Government says it will be setting out negotiating objectives in due course. Richard Torbett, said:

“The US and the UK are two of the most advanced economies in the world and represent the leading edge of global life sciences. We support a future trading relationship that builds on our mutual strengths, so that we can better develop the treatments of the future together.”

TAGS
  • Trade
  • Rest of the World
  • Free Trade Agreements

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.